The Australian market is experiencing a dip amid geopolitical tensions, with investors closely monitoring the impact of supply disruptions and regional conflicts on indices and commodities like oil and gold. In such uncertain times, growth companies with high insider ownership can be particularly appealing as they often reflect strong management confidence and alignment with shareholder interests, making them worthy of attention despite broader market challenges.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Torque Metals (ASX:TOR) 18.6% 94.2% Titomic (ASX:TTT) 14.8% 77.5% Magnetic Resources (ASX:MAU) 33.6% 124.2% Forrestania Resources (ASX:FRS) 32.5% 102.3% Fenix Resources (ASX:FEX) 19.7% 64.7% Cyclopharm (ASX:CYC) 10.4% 117.1% Clinuvel Pharmaceuticals (ASX:CUV) 10.3% 27.1% Austral Resources Australia (ASX:AR1) 18.9% 39.1% Adveritas (ASX:AV1) 17.9% 109.9% Advanced Energy Minerals (ASX:AEM) 37.5% 48.4%

Click here to see the full list of 114 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Beetaloo Energy Australia

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beetaloo Energy Australia Limited, along with its subsidiaries, is involved in the production and sale of oil and natural gas in Australia, with a market capitalization of A$429.21 million.

Operations: The company's revenue is derived from the production and sale of oil and natural gas within Australia.

Insider Ownership: 19%

Return On Equity Forecast: N/A (2028 estimate)

Beetaloo Energy Australia is poised for significant growth, with earnings expected to increase by 93.81% annually and revenue projected to grow at 108.8% per year, surpassing the Australian market average of 5.9%. Despite minimal current revenue (A$14K), the company is forecasted to become profitable within three years. However, shareholders have faced dilution over the past year and recent insider trading data is unavailable. CEO Alexander Underwood recently presented at the ASX Small Caps Conference in Sydney.

Dive into the specifics of Beetaloo Energy Australia here with our thorough growth forecast report. The valuation report we've compiled suggests that Beetaloo Energy Australia's current price could be inflated.ASX:BTL Earnings and Revenue Growth as at Mar 2026

Emerald Resources

Simply Wall St Growth Rating: ★★★★★★

Overview: Emerald Resources NL is involved in the exploration and development of mineral reserves in Cambodia and Australia, with a market cap of A$3.43 billion.

Operations: The company generates revenue primarily from its mine operations, totaling A$446.92 million.

Story Continues

Insider Ownership: 18.4%

Return On Equity Forecast: 42% (2028 estimate)

Emerald Resources is set for robust growth, with earnings forecasted to rise by 51.1% annually and revenue by 43.6%, outpacing the Australian market. Recent leadership changes, including Josh Redmond's appointment as COO, support its expansion efforts at key projects in Australia and Cambodia. The company reported improved half-year earnings of A$73.12 million on sales of A$257.04 million, reflecting operational strength despite no recent insider trading activity over the past three months.

Get an in-depth perspective on Emerald Resources' performance by reading our analyst estimates report here. The analysis detailed in our Emerald Resources valuation report hints at an deflated share price compared to its estimated value.ASX:EMR Earnings and Revenue Growth as at Mar 2026

Mesoblast

Simply Wall St Growth Rating: ★★★★★★

Overview: Mesoblast Limited, with a market cap of A$2.76 billion, develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland.

Operations: The company's revenue is primarily derived from the development of its cell technology platform for commercialization, totaling $65.38 million.

Insider Ownership: 34%

Return On Equity Forecast: 33% (2028 estimate)

Mesoblast is poised for significant growth, with revenue expected to increase by 45.2% annually, surpassing the Australian market's average. Insider confidence is evident as insiders have been buying more shares than selling recently. The company anticipates becoming profitable within three years, driven by its innovative cell therapy products like Ryoncil and rexlemestrocel-L. Recent executive appointments aim to enhance clinical development and medical affairs, supporting Mesoblast's strategic expansion in both pediatric and adult inflammatory conditions.

Unlock comprehensive insights into our analysis of Mesoblast stock in this growth report. Our valuation report unveils the possibility Mesoblast's shares may be trading at a premium.ASX:MSB Ownership Breakdown as at Mar 2026

Next Steps

Click through to start exploring the rest of the 111 Fast Growing ASX Companies With High Insider Ownership now. Contemplating Other Strategies? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:BTL ASX:EMR and ASX:MSB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments